Suzhou Zelgen Biopharmaceuticals Co.,ltd

This study tests a new drug called ZG006 combined with standard immunotherapy (with or without chemotherapy) as a first treatment for people with extensive-stage small cell lung cancer. About 100 adults aged 18-75 will take part to see if the combination is safe and how well it w…

This study tests whether combining two experimental drugs (ZG006 and ZG005) can shrink tumors in people with advanced small cell lung cancer or neuroendocrine carcinoma. About 350 adults aged 18-70 will receive the combination to check safety and effectiveness. The goal is to see…

This study tests two experimental drugs, ZG005 and gecacitinib, with or without bevacizumab, in people with advanced cervical cancer. The goal is to see if the combination is safe and can shrink tumors. About 120 women aged 18-75 with confirmed advanced cervical cancer will take …

This study tests a combination of two experimental drugs, ZGGS18 and ZG005, in people with advanced solid tumors (cervical, liver, neuroendocrine, or lung cancer) that have stopped responding to standard treatments. The goal is to find a safe dose and see if the drugs can shrink …

This study tests a new drug called ZGGS18 in people with advanced solid tumors that have not responded to standard treatments. The main goals are to find a safe dose and understand how the drug behaves in the body. About 222 participants will take part in this early-phase trial.

This study tests a combination of two drugs, ZG005 and gecacitinib, in about 60 adults with relapsed or refractory lymphoma (cancer that returned or didn't respond to prior therapy). The first part finds a safe dose; the second part checks if the combo shrinks tumors. Participant…

This study tests an experimental drug called ZG006 in people with advanced small cell lung cancer or neuroendocrine carcinoma. The first part finds a safe dose, and the second part checks how well it shrinks tumors. About 265 adults aged 18 to 75 with good performance status are …

This study tests an experimental drug called ZGGS34 in people with advanced solid tumors that have not responded to standard treatments. The trial has two parts: first, finding a safe dose, then testing how well ZGGS34 works alone or with chemotherapy in tumors that have a specif…

This study tests a new drug called ZG006 in people with small cell lung cancer or neuroendocrine carcinoma who have run out of standard treatments or can't tolerate them. The goal is to find a safe dose and see if the drug can shrink tumors. About 54 adults aged 18 to 75 will tak…

This study tests a new drug called ZG006 against standard chemotherapy in 420 adults with small cell lung cancer that has come back. The main goal is to see if ZG006 helps people live longer. Participants will be randomly assigned to receive either ZG006 or a chemotherapy chosen …

This study tests a new drug called ZG005 combined with standard chemotherapy (gemcitabine and cisplatin) as a first treatment for people with advanced gallbladder cancer. About 60 participants will receive the combination to see if it shrinks tumors and how safe it is. The goal i…

This study tests a new two-drug combination (ZG005 and gecacitinib) in people with advanced non-small cell lung cancer that has not responded to standard PD-1/L1 therapy. The goal is to see if the combination is safe and can shrink tumors. About 50 adults aged 18 to 75 will take …